Tanimura K

No ORCID on file · 4 papers in corpus
2025
Pregnancy outcomes in women with anti-β2-glycoprotein I/human leukocyte antigen-DR autoantibodies receiving assisted reproductive technology: a prospective cohort study.
Frontiers in immunology ·doi:10.3389/fimmu.2025.1626862

ObjectiveThis study aimed to assess whether anti-β2-glycoprotein I (β2GPI)/human leukocyte antigen (HLA)-DR autoantibodies are associated with pregnancy outcomes in women with infertility receiving assisted reproductive technology (ART) in …

2024
Low-dose aspirin and heparin treatment improves pregnancy outcome in recurrent pregnancy loss women with anti-β2-glycoprotein I/HLA-DR autoantibodies: a prospective, multicenter, observational study.
Frontiers in immunology ·doi:10.3389/fimmu.2024.1445852

IntroductionAnti-β2-glycoprotein I (β2GPI)/human leukocyte antigen (HLA)-DR antibodies may be a risk factor for recurrent pregnancy loss (RPL). The therapeutic modality for women with RPL and anti-β2GPI/HLA-DR antibody positivity has not be…

2023
Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes.
International journal of molecular sciences ·doi:10.3390/ijms241310958

Anti-β2-glycoprotein I/HLA-DR (anti-β2GPI/HLA-DR) antibody has been reported to be associated with antiphospholipid syndrome and recurrent pregnancy loss (RPL). We conducted a prospective multicenter cross-sectional study aimed at evaluatin…

article 2023
Anti-β2-glycoprotein I/HLA-DR antibody in infertility
Journal of reproductive immunology ·doi:10.1016/j.jri.2023.103955

To evaluate whether anti-β2-Glycoprotein I/HLA-DR (anti-β2GPI/HLA-DR) antibody is associated with pathophysiology of infertility, 224 women with infertility were enrolled from July 2020 to December 2021 in this prospective study. The serum …